Importantly, because incomplete T cell differentiation may arise early in the course of tumor progression and is not overcome by CTLA‐4 or PD‐1 blockade, this form of immune dysfunction may indeed contribute to the innate resistance to checkpoint blockade therapy exhibited by many cancers. The gene discussed is CTLA4; the disease is cancer.